Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-blind Placebo-controlled Multicenter Phase 3 Study of Efficacy and Safety of AR-301 as Adjunct Therapy to Antibiotics in the Treatment of Ventilator-Associated Pneumonia (VAP) Caused by S. Aureus

NCT03816956 is registered in ClinicalTrials.gov with Aridis Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03816956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03816956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-blind Placebo-controlled Multicenter Phase 3 Study of Efficacy and Safety of AR-301 as Adjunct Therapy to Antibiotics in the Treatment of Ventilator-Associated Pneumonia (VAP) Caused by S. Aureus
Lead sponsor
Aridis Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
May 3, 2019
Completion date
October 28, 2022
Enrollment
174 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

infection, bacterial, lung infection, pneumonia, ventilator-associated, staphylococcus aureus